Analysts’ Viewpoint
Rise in prevalence of cancer and increase in the geriatric population are driving the global cancer biopsy market. Surge in adoption of liquid biopsies and ongoing developments in biopsy techniques are expected to propel market expansion in the next few years. Furthermore, technological advancements in cancer biopsy are likely to bolster the global cancer biopsy industry during the forecast period.
Development of more accurate and effective biopsy procedures offers lucrative opportunities for market players. Leading companies operating in the market are focusing on strategic launches and collaborations to enhance product offerings and expand global footprint. Post the COVID-19 pandemic, cancer biopsy companies have adopted new technologies, such as liquid biopsies, to detect genetic alterations in cancer patients.
Cancer biopsy is a medical procedure, in which a small sample of tissue is taken from a suspicious or abnormal area in the body to be examined under a microscope. The purpose of a biopsy is to determine whether the tissue sample contains cancer cells and, if so, to identify the type of cancer present.
There are several different methods for performing a biopsy, depending on the type and location of the suspected cancer. The most common types of biopsies are needle biopsy, surgical biopsy, and endoscopic biopsy.
Rise in prevalence of cancer and increase in geriatric population are the major factors driving the global cancer biopsy market value. According to the National Cancer Institute (2020), 60% of cancer patients were 65 or older globally. Surge in adoption of liquid biopsies and ongoing developments in biopsy techniques are the other factors fueling the global market.
According to CanRehab-2022 estimates, 27.5 million new cancer cases would be recorded worldwide by 2040. Additionally, around 83,730 new bladder cancer cases were reported in the U.S. in 2021, along with 284,200 breast cancer cases and 149,500 colon and rectal cancer cases, according to the National Cancer Institute (NCI) 2022 update.
Technological advancements in cancer biopsy and key market players focusing on strategic launches and collaborations to enhance product offerings and expand global footprint are fueling the global cancer biopsy market development.
In 2022, BillionToOne, Inc. released Northstar Select and Northstar Response, its first oncology liquid biopsy products. Currently, a few academic cancer centers can use the items for research purposes.
Emergence of liquid biopsy for cancer diagnosis, screening, prognosis, and treatment monitoring has significantly enhanced the competition and capabilities in the market. This is anticipated to propel the market during the forecast period.
The COVID-19 pandemic has had a significant impact on the global market. Hospital visits were significantly reduced during the early stages due to social isolation policies, and only patients with emergencies were permitted. Thus, cancer biopsies declined in 2020, which hampered the market.
After the pandemic in mid-2020, however, technological advancements in cancer biopsies propelled the market. During the later stages of the pandemic, usage of liquid biopsies to identify genetic changes in cancer patients became more popular.
In terms of product, the kits & reagents segment accounted for largest global cancer biopsy market share in 2022. The trend is expected to continue during the forecast period. Rise in usage of kits & reagents due to surge in cancer patients is driving the segment. Furthermore, increase in availability of technologically advanced kits & reagents are propelling the segment.
Based on type, the liquid biopsy segment dominated the global market in 2022. This is ascribed to introduction of liquid biopsies that have drastically revolutionized the field of clinical oncology into an effective, minimally invasive tumor detection method used for tumor screening and early detection of recurrence, and devising personalized therapeutic regimens.
According to a study published in PMC Journal in September 2021, researchers suggested performing liquid biopsies as a valid and more expedient diagnostic method for treating lung cancer patients during the COVID-19 period.
In terms of application, the breast cancer segment accounted for larger share of the global cancer biopsy market in 2022. This is ascribed to increase in incidence of breast cancer across the globe. The 2022 update by Breastcancer.org indicated that an estimated 51,400 new cases of non-invasive (in situ) breast cancer and 287,850 cases of invasive breast cancer were reported among U.S. women in 2022.
Usage of biopsies for breast cancer screening is increasing, and core-needle biopsy is preferred over surgical biopsy, according to the American Cancer Society's (ACS) January 2022 update. Hence, rise in usage of cancer biopsies for breast cancer screening is driving the segment.
According to cancer biopsy market trends, North America accounted for significant share of the global market in 2022. This is ascribed to technological advancements, high burden of cancer prevalence, and increase in product approval and launches.
Rise in adoption of liquid biopsies across the U.S. is attributed to several strategies adopted by government authorities. For instance, at the American Society of Clinical Oncology (ASCO) 2022, liquid biopsy companies and top cancer researchers presented various liquid biopsy studies for different types of cancer.
The burden of cancer is increasing across countries in North America. As per data published by the National Center for Health Statistics, nearly 1,958,310 new cancer cases and 609,820 cancer deaths are projected to be recorded in the U.S. in 2023
As per the cancer biopsy market forecast, the industry in Asia Pacific is expected to witness robust growth during the forecast period. This is ascribed to high number of cancer patients, growing preference for non-invasive procedures among the population for early detection, adoption of advanced biopsy techniques, and research & collaborations for advanced cancer diagnosis.
The report concludes with the company profiles section that includes key information about the major players. Key players focus on strategies such as new product launches, mergers, and partnerships & collaborations to compete in the marketplace.
Leading companies operating in the market are Abbott Laboratories, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Hologic, Inc., Danaher Corporation, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Illumina, Inc., Siemens Healthineers, GE Healthcare, Bio-Rad Laboratories, Inc., QIAGEN, and Olympus Corporation.
Prominent players have been profiled in the cancer biopsy market report based on parameters such as company overview, financial overview, strategies, portfolio, segments, and recent developments.
| Attribute | Detail |
|---|---|
|
Size in 2022 |
US$ 24.7 Bn |
|
Forecast (Value) in 2031 |
More than US$ 62.0 Bn |
|
Growth Rate (CAGR) |
11.4% |
|
Forecast Period |
2023-2031 |
|
Historical Data Available for |
2017-2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global industry was valued at US$ 24.7 Bn in 2022.
It is projected to reach more than US$ 66.0 Bn by 2031.
It is anticipated to expand at a CAGR of 11.4% from 2023 to 2031.
Rise in prevalence of cancer, increase in geriatric population, surge in adoption of liquid biopsies, and ongoing developments in biopsy techniques are propelling the market.
The breast cancer segment accounted for more than 12.0% share in 2022.
North America is expected to account for the largest share of the market from 2023 to 2031.
Abbott Laboratories, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Hologic, Inc., Danaher Corporation, Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., Illumina, Inc., Siemens Healthineers, GE Healthcare, Bio-Rad Laboratories, Inc., QIAGEN, and Olympus Corporation are the prominent players in the market.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cancer Biopsy Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Cancer Biopsy Market Analysis and Forecast, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Cancer Prevalence & Incidence, by Region
5.2. Technological Advancements
5.3. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
5.4. Reimbursement Scenario by Region/Globally
5.5. Value Chain Analysis
6. Global Cancer Biopsy Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product, 2017-2031
6.3.1. Platforms & Instruments
6.3.2. Kits & Reagents
6.3.3. Services
6.4. Market Attractiveness Analysis, by Product
7. Global Cancer Biopsy Market Analysis and Forecast, by Type
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Type, 2017-2031
7.3.1. Tissue Biopsies
7.3.1.1. Needle Biopsies
7.3.1.2. Surgical Biopsies
7.3.2. Liquid Biopsies
7.3.3. Others
7.4. Market Attractiveness Analysis, by Type
8. Global Cancer Biopsy Market Analysis and Forecast, by Application
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Application, 2017-2031
8.3.1. Breast Cancer
8.3.2. Colorectal Cancer
8.3.3. Cervical Cancer
8.3.4. Lung Cancer
8.3.5. Prostate Cancer
8.3.6. Skin Cancer
8.3.7. Blood Cancer
8.3.8. Kidney Cancer
8.3.9. Liver Cancer
8.3.10. Pancreatic Cancer
8.3.11. Ovarian Cancer
8.3.12. Others
8.4. Market Attractiveness Analysis, by Application
9. Global Cancer Biopsy Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017-2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Cancer Biopsy Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Product, 2017-2031
10.2.1. Platforms & Instruments
10.2.2. Kits & Reagents
10.2.3. Services
10.3. Market Value Forecast, by Type, 2017-2031
10.3.1. Tissue Biopsies
10.3.1.1. Needle Biopsies
10.3.1.2. Surgical Biopsies
10.3.2. Liquid Biopsies
10.3.3. Others
10.4. Market Value Forecast, by Application, 2017-2031
10.4.1. Breast Cancer
10.4.2. Colorectal Cancer
10.4.3. Cervical Cancer
10.4.4. Lung Cancer
10.4.5. Prostate Cancer
10.4.6. Skin Cancer
10.4.7. Blood Cancer
10.4.8. Kidney Cancer
10.4.9. Liver Cancer
10.4.10. Pancreatic Cancer
10.4.11. Ovarian Cancer
10.4.12. Others
10.5. Market Value Forecast, by Country, 2017-2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Product
10.6.2. By Type
10.6.3. By Application
10.6.4. By Country
11. Europe Cancer Biopsy Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2017-2031
11.2.1. Platforms & Instruments
11.2.2. Kits & Reagents
11.2.3. Services
11.3. Market Value Forecast, by Type, 2017-2031
11.3.1. Tissue Biopsies
11.3.1.1. Needle Biopsies
11.3.1.2. Surgical Biopsies
11.3.2. Liquid Biopsies
11.3.3. Others
11.4. Market Value Forecast, by Application, 2017-2031
11.4.1. Breast Cancer
11.4.2. Colorectal Cancer
11.4.3. Cervical Cancer
11.4.4. Lung Cancer
11.4.5. Prostate Cancer
11.4.6. Skin Cancer
11.4.7. Blood Cancer
11.4.8. Kidney Cancer
11.4.9. Liver Cancer
11.4.10. Pancreatic Cancer
11.4.11. Ovarian Cancer
11.4.12. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Product
11.6.2. By Type
11.6.3. By Application
11.6.4. By Country/Sub-region
12. Asia Pacific Cancer Biopsy Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2017-2031
12.2.1. Instruments
12.2.2. Kits & Reagents
12.2.3. Services
12.3. Market Value Forecast, by Type, 2017-2031
12.3.1. Tissue Biopsies
12.3.1.1. Needle Biopsies
12.3.1.2. Surgical Biopsies
12.3.2. Liquid Biopsies
12.3.3. Others
12.4. Market Value Forecast, by Application, 2017-2031
12.4.1. Breast Cancer
12.4.2. Colorectal Cancer
12.4.3. Cervical Cancer
12.4.4. Lung Cancer
12.4.5. Prostate Cancer
12.4.6. Skin Cancer
12.4.7. Blood Cancer
12.4.8. Kidney Cancer
12.4.9. Liver Cancer
12.4.10. Pancreatic Cancer
12.4.11. Ovarian Cancer
12.4.12. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Product
12.6.2. By Type
12.6.3. By Application
12.6.4. By Country/Sub-region
13. Latin America Cancer Biopsy Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2017-2031
13.2.1. Platforms & Platforms & Instruments
13.2.2. Kits & Reagents
13.2.3. Services
13.3. Market Value Forecast, by Type, 2017-2031
13.3.1. Tissue Biopsies
13.3.1.1. Needle Biopsies
13.3.1.2. Surgical Biopsies
13.3.2. Liquid Biopsies
13.3.3. Others
13.4. Market Value Forecast, by Application, 2017-2031
13.4.1. Breast Cancer
13.4.2. Colorectal Cancer
13.4.3. Cervical Cancer
13.4.4. Lung Cancer
13.4.5. Prostate Cancer
13.4.6. Skin Cancer
13.4.7. Blood Cancer
13.4.8. Kidney Cancer
13.4.9. Liver Cancer
13.4.10. Pancreatic Cancer
13.4.11. Ovarian Cancer
13.4.12. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Product
13.6.2. By Type
13.6.3. By Application
13.6.4. By Country/Sub-region
14. Middle East & Africa Cancer Biopsy Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product, 2017-2031
14.2.1. Platforms & Instruments
14.2.2. Kits & Reagents
14.2.3. Services
14.3. Market Value Forecast, by Type, 2017-2031
14.3.1. Tissue Biopsies
14.3.1.1. Needle Biopsies
14.3.1.2. Surgical Biopsies
14.3.2. Liquid Biopsies
14.3.3. Others
14.4. Market Value Forecast, by Application, 2017-2031
14.4.1. Breast Cancer
14.4.2. Colorectal Cancer
14.4.3. Cervical Cancer
14.4.4. Lung Cancer
14.4.5. Prostate Cancer
14.4.6. Skin Cancer
14.4.7. Blood Cancer
14.4.8. Kidney Cancer
14.4.9. Liver Cancer
14.4.10. Pancreatic Cancer
14.4.11. Ovarian Cancer
14.4.12. Others
14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Product
14.6.2. By Type
14.6.3. By Application
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2022
15.3. Company Profiles
15.3.1. Abbott Laboratories
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Becton, Dickinson and Company
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. F. Hoffmann-La Roche Ltd.
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Hologic, Inc.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Danaher Corporation
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Thermo Fisher Scientific, Inc.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. Agilent Technologies, Inc.
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Illumina, Inc.
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Siemens Healthineers
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
15.3.10. GE Healthcare
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview
15.3.11. Bio-Rad Laboratories, Inc.
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Product Portfolio
15.3.11.3. Financial Overview
15.3.11.4. SWOT Analysis
15.3.11.5. Strategic Overview
15.3.12. Olympus Corporation
15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.12.2. Product Portfolio
15.3.12.3. Financial Overview
15.3.12.4. SWOT Analysis
15.3.12.5. Strategic Overview
15.3.13. QIAGEN
15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.13.2. Product Portfolio
15.3.13.3. Financial Overview
15.3.13.4. SWOT Analysis
15.3.13.5. Strategic Overview
List of Tables
Table 01: Global Cancer Biopsy Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 02: Global Cancer Biopsy Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 03: Global Cancer Biopsy Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 04: Global Cancer Biopsy Market Value (US$ Mn) Forecast, by Tissue Biopsies, 2017-2031
Table 05: Global Cancer Biopsy Market Value (US$ Mn) Forecast, by Liquid Biopsies, 2017-2031
Table 06: Global Cancer Biopsy Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 07: North America Cancer Biopsy Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 08: North America Cancer Biopsy Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 09: North America Cancer Biopsy Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 10: North America Cancer Biopsy Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 11: North America Cancer Biopsy Market Value (US$ Mn) Forecast, by Tissue Biopsies, 2017-2031
Table 12: North America Cancer Biopsy Market Value (US$ Mn) Forecast, by Liquid Biopsies, 2017-2031
Table 13: Europe Cancer Biopsy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 14: Europe Cancer Biopsy Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 15: Europe Cancer Biopsy Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 16: Europe Cancer Biopsy Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 17: Europe Cancer Biopsy Market Value (US$ Mn) Forecast, by Tissue Biopsies, 2017-2031
Table 18: Europe Cancer Biopsy Market Value (US$ Mn) Forecast, by Liquid Biopsies, 2017-2031
Table 19: Asia Pacific Cancer Biopsy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 20: Asia Pacific Cancer Biopsy Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 21: Asia Pacific Cancer Biopsy Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 22: Asia Pacific Cancer Biopsy Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 23: Asia Pacific Cancer Biopsy Market Value (US$ Mn) Forecast, by Tissue Biopsies, 2017-2031
Table 24: Asia Pacific Cancer Biopsy Market Value (US$ Mn) Forecast, by Liquid Biopsies, 2017-2031
Table 25: Latin America Cancer Biopsy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 26: Latin America Cancer Biopsy Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 27: Latin America Cancer Biopsy Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 28: Latin America Cancer Biopsy Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 29: Latin America Cancer Biopsy Market Value (US$ Mn) Forecast, by Tissue Biopsies, 2017-2031
Table 30: Latin America Cancer Biopsy Market Value (US$ Mn) Forecast, by Liquid Biopsies, 2017-2031
Table 31: Middle East & Africa Cancer Biopsy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 32: Middle East & Africa Cancer Biopsy Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 33: Middle East & Africa Cancer Biopsy Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 34: Middle East & Africa Cancer Biopsy Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 35: Middle East & Africa Cancer Biopsy Market Value (US$ Mn) Forecast, by Tissue Biopsies, 2017-2031
Table 36: Middle East & Africa Cancer Biopsy Market Value (US$ Mn) Forecast, by Liquid Biopsies, 2017-2031
List of Figures
Figure 01: Global Cancer Biopsy Market Value Share Analysis, by Product, 2022 and 2031
Figure 02: Global Cancer Biopsy Market Attractiveness Analysis, Product, 2023-2031
Figure 03: Global Cancer Biopsy Market Revenue (US$ Mn), by Platforms & Instruments, 2017-2031
Figure 04: Global Cancer Biopsy Market Revenue (US$ Mn), by Kits & Reagents, 2017-2031
Figure 04: Global Cancer Biopsy Market Revenue (US$ Mn), by Services, 2017-2031
Figure 05: Global Cancer Biopsy Market Value Share Analysis, by Type, 2022 and 2031
Figure 06: Global Cancer Biopsy Market Attractiveness Analysis, by Type, 2023-2031
Figure 07: Global Cancer Biopsy Market Revenue (US$ Mn), by Tissue Biopsies, 2017-2031
Figure 08: Global Cancer Biopsy Market Revenue (US$ Mn), by Liquid Biopsies, 2017-2031
Figure 09: Global Cancer Biopsy Market Value Share Analysis, by Application, 2022 and 2031
Figure 10: Global Cancer Biopsy Market Attractiveness Analysis, Application, 2023-2031
Figure 11: Global Cancer Biopsy Market Revenue (US$ Mn), by Breast Cancer, 2017-2031
Figure 12: Global Cancer Biopsy Market Revenue (US$ Mn), by Colorectal Cancer, 2017-2031
Figure 13: Global Cancer Biopsy Market Revenue (US$ Mn), by Cervical Cancer 2022 and 2031
Figure 14: Global Cancer Biopsy Market Revenue (US$ Mn), Lung Cancer, 2023-2031
Figure 15: Global Cancer Biopsy Market Revenue (US$ Mn), by Prostate Cancer, 2017-2031
Figure 16: Global Cancer Biopsy Market Revenue (US$ Mn), by Skin Cancer, 2017-2031
Figure 17: Global Cancer Biopsy Market Revenue (US$ Mn), by Blood Cancer, 2017-2031
Figure 18: Global Cancer Biopsy Market Revenue (US$ Mn), Kidney Cancer, 2023-2031
Figure 19: Global Cancer Biopsy Market Revenue (US$ Mn), by Liver Cancer, 2017-2031
Figure 20: Global Cancer Biopsy Market Revenue (US$ Mn), by Pancreatic Cancer, 2017-2031
Figure 21: Global Cancer Biopsy Market Revenue (US$ Mn), by Ovarian Cancer, 2017-2031
Figure 22: Global Cancer Biopsy Market Revenue (US$ Mn), by Others, 2017-2031
Figure 23: Global Cancer Biopsy Market Value Share Analysis, by Region, 2022 and 2031
Figure 24: Global Cancer Biopsy Market Attractiveness Analysis, by Region, 2023-2031
Figure 25: North America Cancer Biopsy Market Value (US$ Mn) Forecast, 2017-2031
Figure 26: North America Cancer Biopsy Market Value Share Analysis, by Country, 2022 and 2031
Figure 27: North America Cancer Biopsy Market Attractiveness Analysis, by Country, 2023-2031
Figure 28: North America Cancer Biopsy Market Value Share Analysis, by Product, 2022 and 2031
Figure 29: North America Cancer Biopsy Market Attractiveness Analysis, Product, 2023-2031
Figure 30: North America Cancer Biopsy Market Value Share Analysis, by Type, 2022 and 2031
Figure 31: North America Cancer Biopsy Market Attractiveness Analysis, Type, 2023-2031
Figure 32: North America Cancer Biopsy Market Value Share Analysis, by Application, 2022 and 2031
Figure 33: North America Cancer Biopsy Market Attractiveness Analysis, by Application, 2023-2031
Figure 34: Europe Cancer Biopsy Market Value (US$ Mn) Forecast, 2017-2031
Figure 35: Europe Cancer Biopsy Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 36: Europe Cancer Biopsy Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 37: Europe Cancer Biopsy Market Value Share Analysis, by Product, 2022 and 2031
Figure 38: Europe Cancer Biopsy Market Attractiveness Analysis, Product, 2023-2031
Figure 39: Europe Cancer Biopsy Market Value Share Analysis, by Type, 2022 and 2031
Figure 40: Europe Cancer Biopsy Market Attractiveness Analysis, by Type, 2023-2031
Figure 41: Europe Cancer Biopsy Market Value Share Analysis, by Application, 2022 and 2031
Figure 42: Europe Cancer Biopsy Market Attractiveness Analysis, by Application, 2023-2031
Figure 43: Asia Pacific Cancer Biopsy Market Value (US$ Mn) Forecast, 2017-2031
Figure 44: Asia Pacific Cancer Biopsy Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 45: Asia Pacific Cancer Biopsy Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 46: Asia Pacific Cancer Biopsy Market Value Share Analysis, by Product, 2022 and 2031
Figure 47: Asia Pacific Cancer Biopsy Market Attractiveness Analysis, Product, 2023-2031
Figure 48: Asia Pacific Cancer Biopsy Market Value Share Analysis, by Type, 2022 and 2031
Figure 49: Asia Pacific Cancer Biopsy Market Attractiveness Analysis, by Type, 2023-2031
Figure 50: Asia Pacific Cancer Biopsy Market Value Share Analysis, by Application, 2022 and 2031
Figure 51: Asia Pacific Cancer Biopsy Market Attractiveness Analysis, by Application, 2023-2031
Figure 52: Latin America Cancer Biopsy Market Value (US$ Mn) Forecast, 2017-2031
Figure 53: Latin America Cancer Biopsy Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 54: Latin America Cancer Biopsy Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 55: Latin America Cancer Biopsy Market Value Share Analysis, by Product, 2022 and 2031
Figure 56: Latin America Cancer Biopsy Market Attractiveness Analysis, Product, 2023-2031
Figure 57: Latin America Cancer Biopsy Market Value Share Analysis, by Type, 2022 and 2031
Figure 58: Latin America Cancer Biopsy Market Attractiveness Analysis, Type, 2023-2031
Figure 59: Latin America Cancer Biopsy Market Value Share Analysis, by Application, 2022 and 2031
Figure 60: Latin America Cancer Biopsy Market Attractiveness Analysis, by Application, 2023-2031
Figure 61: Middle East & Africa Cancer Biopsy Market Value (US$ Mn) Forecast, 2017-2031
Figure 62: Middle East & Africa Cancer Biopsy Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 63: Middle East & Africa Cancer Biopsy Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 64: Middle East & Africa Cancer Biopsy Market Value Share Analysis, by Product, 2022 and 2031
Figure 65: Middle East & Africa Cancer Biopsy Market Attractiveness Analysis, Product, 2023-2031
Figure 66: Middle East & Africa Cancer Biopsy Market Value Share Analysis, by Type, 2022 and 2031
Figure 67: Middle East & Africa Cancer Biopsy Market Attractiveness Analysis, Type, 2023-2031
Figure 68: Middle East & Africa Cancer Biopsy Market Value Share Analysis, by Application, 2022 and 2031
Figure 69: Middle East & Africa Cancer Biopsy Market Attractiveness Analysis, by Application, 2023-2031
Figure 70: Global Cancer Biopsy Market Share Analysis, by Company 2022
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Cancer Biopsy Market
*86 figures and 60 tables includes